Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term biochemical failure. Found 10 abstracts

Turaka A, Buyyounouski MK, Hanlon AL, Horwitz EM, Greenberg RE, Movsas B. Hypoxic Prostate/Muscle PO2 Ratio Predicts for Outcome in Patients With Localized Prostate Cancer: Long-Term Results. International Journal of Radiation Oncology Biology Physics. 2012 Mar;82(3):E433-E439.   PMCID: not NIH funded
Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, Blute ML, Buyyounouski MK. Long-Term Survival After Radical Prostatectomy Versus External-Beam Radiotherapy for Patients With High-Risk Prostate Cancer. Cancer. 2011 Jul;117(3):2883-91.   PMCID: PMC3139725
Klayton TL, Ruth K, Horwitz EM, Uzzo RG, Kutikov A, Chen DY, Sobczak M, Buyyounouski MK. Young age under 60 years is not a contraindication to treatment with definitive dose escalated radiotherapy for prostate cancer. Radiotherapy and Oncology. 2011 Dec;101(3):508-12.   PMCID: PMC3225561
Rosenthal SA, Bittner NH, Beyer DC, Demanes DJ, Goldsmith BJ, Horwitz EM, Ibbott GS, Lee WR, Nag S, Suh WW, Potters L. AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO) AND AMERICAN COLLEGE OF RADIOLOGY (ACR) PRACTICE GUIDELINE FOR THE TRANSPERINEAL PERMANENT BRACHYTHERAPY OF PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2011 Feb;79(2):335-41.   PMCID: PMCID: PMC3030655 [Available on 2012/2/1]
Ray ME, Bae K, Hussain MH, Hanks GE, Shipley WU, Sandler HM. Potential Surrogate Endpoints for Prostate Cancer Survival: Analysis of a Phase III Randomized Trial. Journal of the National Cancer Institute. 2009 Feb;101(4):228-36.   PMCID: PMC2734115
Williams SG, Buyyounouski MK, Pickles T, Kestin L, Martinez A, Hanlon AL, Duchesne GM. Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: Statistical significance without predictive performance. International Journal of Radiation Oncology Biology Physics. 2008 Mar;70(4):1169-75.
Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, Pollack A. Radiation dose and late failures in prostate cancer. International Journal of Radiation Oncology Biology Physics. 2007 Mar;67(4):1074-81.
Thames HD, Kuban DA, DeSilvio ML, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL. Increasing external beam dose for T1-T2 prostate cancer: Effect on risk groups. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2006 Jul;65(4):975-81.
Kuban D, Thames H, Levy L, Horwitz E, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Failure definition-dependent differences in outcome following radiation for localized prostate cancer: Can one size fit all?. International Journal of Radiation Oncology Biology Physics. 2005 Feb;61(2):409-14.
Pollack A, Zagars GK, Antolak JA, Kuban DA, Rosen II. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: Analysis of a prostate cancer randomized radiation dose escalation trial. International Journal of Radiation Oncology Biology Physics. 2002 Nov;54(3):677-85.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term biochemical failure

biochemical failure radiotherapy radiation-therapy carcinoma prostate cancer external-beam radiation phase-iii trial group protocol 92-02 androgen deprivation radical prostatectomy radiation dose EXTERNAL-BEAM RADIATION multi-institutional analysis Brachytherapy therapy THERAPY Prostatic neoplasms hormonal-therapy CLINICAL UTILITY po-2 CONFORMAL RADIOTHERAPY RISK Safety irradiation PROGNOSTIC MODELS intermediate-risk multiinstitutional analysis survival outcomes time trends disease-free survival androgen-deprivation therapy angiogenesis iii randomized trial Age factors Nuclear Medicine & Medical Imaging Radiology therapeutic radiology Prostate FOLLOW-UP american society Dosimetry Biochemical failure seed implantation RADICAL PROSTATECTOMY defines disease freedom survival men younger prognostic models Radiotherapy adjuvant therapy MEN ANTIGEN risk radical prostatectomy prostate cancer-radiation therapy-androgen-deprivation therapy-prostate-specific antigen ASTRO failure definition Quality Assurance era competing therapy oncology group antigen nadir Hypoxia definitions RECURRENCE randomized-trial expression distant metastasis external-beam radiotherapy DISTANT METASTASIS androgen suppression follow-up Prostate cancer free survival PSA disease-free survival Oncology conformal radiotherapy RANDOMIZED TRIAL risk groups oxygenation tumor Conformal interobserver variability antigen era Prostate Cancer clinical disease-free survival ANDROGEN DEPRIVATION METASTATIC DISSEMINATION hazard function patient age prostate biopsy PREOPERATIVE NOMOGRAM BIOCHEMICAL FAILURE Eppendorf interstitial brachytherapy colon-cancer prostate-specific antigen nadir LOCAL-CONTROL randomized multicenter trial
Last updated on Thursday, July 02, 2020